Shu Chuen Li

Biography

Professor Shu Chuen Li is Chair Professor and Discipline Convenor, Discipline of Pharmacy and Experimental Pharmacology. Before taking up the present position, Professor Li has worked as an academic at the National University of Singapore and as Acting Director and Deputy Director, Pharmaceutical Evaluation Section (PES) of Pharmaceutical Benefits Branch, Commonwealth Department of Health & Ageing in Canberra. During his period in Singapore, besides his academic appointment, Professor Li also served as the Visiting Specialist and Consultant to the Health Sciences Authority (which is the Singaporean equivalent of FDA in the USA and TGA in Australia). In this capacity, Professor Li has been instrumental in developing the Pharmacoeconomics and Drug Utilization Unit at the Centre for Drug Administration, Health Sciences Authority and in organizing several of the first ever pharmaceoconomics and outcomes conferences in the region. In his capacity as Acting Director and Deputy Director of PES in Australia, Professor Li was among the few pioneers that put the principles of pharmacoeconomic evaluation into practice for regulatory affairs, and has been involved in the implementation of the first version of the Australian Pharmacoeconomics Guidelines and the development of the second version of the same Guidelines. Professor Li has been very active in his research area of pharmacoeconomics and outcomes research as well as pharmacy practice. He has published more than 250 peer review articles and conference abstracts on the subjects. In the past few years, Professor Li has been invited to present more than 100 lectures and panel speeches about pharmacy practice, drug policies and pharmacoeconomic applications in various countries and jurisdictions. Professor Li was a Director on the ISPOPR Board of Directors from 2006 to 2008, and a founding member of the ISPOR Asia Consortium.  Professor Shu Chuen Li is Chair Professor and Discipline Convenor, Discipline of Pharmacy and Experimental Pharmacology. Before taking up the present position, Professor Li has worked as an academic at the National University of Singapore and as Acting Director and Deputy Director, Pharmaceutical Evaluation Section (PES) of Pharmaceutical Benefits Branch, Commonwealth Department of Health & Ageing in Canberra. During his period in Singapore, besides his academic appointment, Professor Li also served as the Visiting Specialist and Consultant to the Health Sciences Authority (which is the Singaporean equivalent of FDA in the USA and TGA in Australia). In this capacity, Professor Li has been instrumental in developing the Pharmacoeconomics and Drug Utilization Unit at the Centre for Drug Administration, Health Sciences Authority and in organizing several of the first ever pharmaceoconomics and outcomes conferences in the region. In his capacity as Acting Director and Deputy Director of PES in Australia, Professor Li was among the few pioneers that put the principles of pharmacoeconomic evaluation into practice for regulatory affairs, and has been involved in the implementation of the first version of the Australian Pharmacoeconomics Guidelines and the development of the second version of the same Guidelines. Professor Li has been very active in his research area of pharmacoeconomics and outcomes research as well as pharmacy practice. He has published more than 250 peer review articles and conference abstracts on the subjects. In the past few years, Professor Li has been invited to present more than 100 lectures and panel speeches about pharmacy practice, drug policies and pharmacoeconomic applications in various countries and jurisdictions. Professor Li was a Director on the ISPOPR Board of Directors from 2006 to 2008, and a founding member of the ISPOR Asia Consortium. 

Research Interest

Complications of Hypoglycemia Diabetes and Alcohol Diabetes and Weight Loss Diabetes Cholestrol Diabetes for Dummies Diabetes Lipid Metabolism